Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects
Journal of Aerosol Medicine and Pulmonary Drug Delivery · 01.08.2021 · 34 (4) · 251-261
DOI: 10.1089/jamp.2020.1651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Aerosol Medicine and Pulmonary Drug Delivery, online erschienen am 03.08.2021. Verfasst von Michael A Eldon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometics Consultant, Emerald Hills, California, USA. Hauptthemen laut MEDLINE: Vardenafil Dihydrochloride. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
RT234 (vardenafil inhalation powder) is being developed for pulmonary administration “as needed”, to acutely improve exercise tolerance and symptoms in patients with pulmonary arterial hypertension (PAH).
Methods
This single-center, open-label, randomized study in 32 healthy adult subjects evaluated single and multiple inhalation doses of RT234, for safety, tolerability, and pharmacokinetics (PKs).
Results
RT234 was generally safe and well tolerated at single doses of 0.2–2.4 mg and after repeated dose administration of up to 2.4 mg q4h for four doses daily for 9 days. The most common treatment-emergent adverse events were mild-to-moderate headaches. There was no evidence of pulmonary irritation or inflammation. Vardenafil was absorbed very rapidly after inhalation as RT234, independent of dose level and number of doses administered. The t max occurred at the time that the first blood sample following completion of dosing. After C max was achieved, plasma vardenafil concentrations declined rapidly in an exponential fashion that appeared to be parallel among dose levels. Vardenafil plasma concentrations and PK parameters increased in a dose-proportional manner. Vardenafil systemic exposure was notably greater after oral administration of 20 mg vardenafil tablets (Levitra ® ) than after administration of any dose level of RT234. During repeated dose administration of RT234, C max was attained rapidly following each dose and in a pattern similar to that observed after single-dose administration. Minor accumulation, characterized by very low mean morning predose vardenafil concentrations (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Pharmacometics Consultant, Emerald Hills, California, USA.
- Respira Therapeutics, Inc., Burlingame, California, USA.
- Okikawa and Associates, Inc., Englewood, Florida, USA.
Zitieren
APA
Eldon, M. A., Parsley, E. L., Maurer, M., Tarara, T. E., Okikawa, J., & Weers, J. G. (2021). Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 34(4), 251-261. https://doi.org/10.1089/jamp.2020.1651
Vancouver
Eldon MA, Parsley EL, Maurer M, Tarara TE, Okikawa J, Weers JG. Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021;34(4):251-261. doi:10.1089/jamp.2020.1651
BibTeX
@article{Eldon2021,
author = {Eldon, Michael A and Parsley, Edwin L and Maurer, Mari and Tarara, Thomas E and Okikawa, Jerry and Weers, Jeffry G},
title = {Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects},
journal = {Journal of Aerosol Medicine and Pulmonary Drug Delivery},
year = {2021},
volume = {34},
number = {4},
pages = {251--261},
doi = {10.1089/jamp.2020.1651}
}
EUVIMED